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Table 1
Analysis A: Result of the Randomised Trial
Variable No Brace Group Brace Group Between Groups Difference
Mean difference
(SD)
95% CI
Lower
95% CI
Upper
Mean difference
(SD)
95% CI
Lower
95% CI
Upper
Mean difference
(SE)
95% CI
Lower
95% CI
Upper
P
Change in Nominated Pain
VAS @ 6 weeks (0-100 scale)
-1.29 (19.38) -6.39 3.80 -18.16 (21.37) -23.88 -12.44 16.87 (3.82) 9.30 24.43 <0.001
Change in KOOS Pain Subscale
@ 6 weeks (100 - 0)*
2.08 (13.11) -1.28 5.43 8.78 (16.65) 4.36 13.20 -6.70 (2.75) -12.15 -1.25 0.02
Change in KOOS Symptom
Subscale @ 6 weeks(100 - 0)*
-0.34 (10.60) -3.05 2.38 7.83 (12.54) 4.51 11.16 -8.17 (2.13) -12.39 -3.95 <0.001
Change in KOOS ADL
Subscale @ 6 weeks(100 - 0)*
1.03 (12.14) -2.11 4.16 6.67 (12.30) 3.32 10.03 -5.65 (2.29) -10.19 -1.11 0.02
Change in KOOS QoL
Subscale @ 6 weeks(100 - 0)*
1.43 (12.10) -1.79 4.64 5.82 (14.59) 1.80 9.84 -4.39 (2.55) -9.45 0.66 0.09
* Improvement in VAS pain is shown as a decrease, whereas improvement in KOOS scales are shown as an increase.
Table 2
Analysis B: Change After 12 Weeks of Bracing
Variable Both Groups Pooled
Mean
Difference
(SE)
95% CI
Lower
95% CI
Upper
P
Change in Nominated Pain
VAS @ 12 weeks (0-100 scale)
-1.55 (0.21) -1.96 -1.13 <0.001
Change in KOOS Pain
Subscale @ 12 weeks (100 - 0)*
7.95 (1.27) 5.46 10.45 <0.001
Change in KOOS Symptom
Subscale @ 12 weeks (100 - 0)*
6.82 (1.19) 4.48 9.16 <0.001
Change in KOOS ADL
Subscale @ 12 weeks (100 - 0)*
7.32 (1.12) 5.11 9.54 <0.001
Change in KOOS QoL
Subscale @ 12 weeks (100 - 0)*
8.64 (1.33) 6.02 11.26 <0.001
* Improvement in VAS pain is shown as a decrease, whereas improvement in KOOS
scales are shown as an increase.
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COMPARING DIFFERENT PREPARATIONS AND DOSES OF ROSEHIP
POWDER IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE: AN
EXPLORATORY RANDOMIZED ACTIVE-CONTROLLED TRIAL
R. Christensen y,z, S. Tarp y, R.D. Altman x, M. Henriksen y, D.E.
Furst k, E.M. Bartels y, L. Klokker y, M. Boesen y, C.C. Holm y, B.
Danneskiold-Samsøe y, H. Bliddal y. y The Parker Inst., Dept. of
Rheumatology; Copenhagen Univ. Hosp., Frederiksberg, Copenhagen,
Denmark; z Inst. of Sports Sci. and Clinical Biomechanics, Univ. of
Southern Denmark, Odense M, Denmark; xDavid Geffen Sch. of Med.,
Univ. of California, Los Angeles, CA, USA; kDept. of Rheumatology, Univ.
of California, Los Angeles, CA, USA
Purpose: Alternative and complementary therapies are always of
interest to patients. Some evidence from meta-analysis indicates that
rosehip powder might reduce pain in patients with osteoarthritis (OA).
Our aim was to examine the efﬁcacy and safety of the original rosehip
powder, and two different doses of a novel enhanced rosehip powder of
selected rosehips (Rosenoids) in patients with knee OA.
Methods: This was a single-center, 12 week, double-blind, randomized,
active-controlled trial in 150 patients with symptomatic knee OA (Trial
registration: NCT01430481). Patients were stratiﬁed by sex, and
randomly assigned to receive A: ‘Original rosehip powder’ 4500mg/d (6
capsules; n¼49), B: ‘Enhanced rosehip powder’ 4500 mg/d (6 capsules;
n¼50), or C: ‘Enhanced rosehip powder’ 2250 mg/d (3 capsules; n¼51).
Patients were allowed to continue any non-opioid concomitant anal-
gesic therapy; patients were not allowed to use other rosehip prepa-
rations. The primary outcome measure was the change from baseline in
the KOOS-item ‘Pain during walking on ﬂat surface’ graded on a 5-point
Likert scale from 0 (best) to 4 (worst). Secondary outcomes included all
ﬁve KOOS subscales (Function, Quality of life, Pain, Function in sport and
recreation, and Symptoms). All statistical analyses were based on the
Intention-to-Treat (ITT) population (N¼150), replacing missing data
with Last Observation Carried Forward (LOCF) imputation. Data weremodeled and analyzed using ‘PROC MIXED’ based on REstricted
Maximum Likelihood (REML).
Results: At baseline, the average ‘Pain during walking on ﬂat surface’
was 1.3 KOOS item-points. Mean age was 65 years, with average disease
duration of 10 years. During the trial, the attrition rates were equal
across groups (A: 8%, B: 6%, and C: 8%). The change in the primary
outcome was equal across groups (P¼0.95), although the interaction
between time and group indicated a trend for some differences over
time (TimeGroup, P¼0.075). The change in ‘Pain during walking’
assessed after 12 weeks corresponded to average improvements of A
(original, 6 capsules): -0.3 (95% CI: -0.1 to -0.5; appr. 19%), B (enhanced,
6 capsules): -0.3 (-0.1 to -0.5; appr. 24%), and C (enhanced, 3 capsules):
-0.4 (-0.2 to -0.6; appr. 29%). Further, improvements from baseline in
one of the secondary outcomes at 12 weeks, KOOS-symptoms, sup-
ported treatment C - 3 capsules ‘Enhanced rosehip powder’ (8.0 [4.5 to
11.5]) compared to the ‘Original rosehip powder’ 6 capsules (2.1 [-1.4 to
5.6]): Mean difference: 5.97 (0.92 to 11.02) KOOS-symptoms subscale
points. Limitations: Although the three different formulations could be
compared and the study was masked, there was no placebo group, so
actual efﬁcacy could not be ascertained.
Conclusion: The novel ‘Enhanced rosehip powder’ (Rosenoids),
may be more potent than the other formulation (3 capsules equaled
6 capsules per day of the original formulation). This allows one
to prepare appropriate dosing regimens for phase-3-like placebo-
controlled trials.33
SERUM LEVELS OF VITAMIN D AND PARATHYROID HORMONE AND
PROGRESSION OF KNEE OA: THE OSTEOARTHRITIS INITIATIVE STUDY
F. Zhang y, J.B. Driban z, G.H. Lo x, L. Price z, S. Booth k, C.B. Eaton {, B.
Lu #, M. Nevitt yy, R. Jackson zz, C. Garganta z, M.C. Hochberg xx, C.K.
Kwoh kk, T.E. McAlindon z. y Tufts Univ., Boston, MA, USA; z Tufts Med.
Ctr., Boston, MA, USA; xBaylor Coll. of Med., Boston, MA, USA; k Jean
Mayer USDA Human Nutrition Res. Ctr. at Tufts Univ., Boston, MA, USA;
{Brown Univ., Pawtucket, RI, USA; #Harvard Univ., Boston, MA, USA;
yyUniversity of California at San Francisco, San Francisco, CA, USA;
zzOhio State Univ. Med. Ctr., Columbus, OH, USA; xxUniv. of Maryland,
Baltimore, MD, USA; kkUniv. of Pittsburgh, Pittsburgh, MA, USA
Purpose: Vitamin D deﬁciency may play a role in progression of knee
osteoarthritis (OA) but the evidence remains inconsistent and warrants
further characterization. Recent studies have suggested that peri-
articular bone changes are integral to OA onset and progression.
Vitamin D status may inﬂuence peri-articular bone, contributing to the
disease incidence and/or progression. We assessed serum levels of
vitamin D and parathyroid hormone (PTH) in association with
progression of knee OA among 488 participants of the Osteoarthritis
Initiative (OAI) Study.
Methods: Participants in the Bone Ancillary Study were recruited from
the OAI progression subcohort and had at least one knee with both
radiographic evidence of knee OA and pain. They underwent additional
knee dual-energy x-ray absorptiometry scans and knee trabecular
magnetic resonance imaging (MRI) at the 30- or 36-month (baseline)
and 48-month OAI visits (follow-up). Serum 25-hydroxyvitamin D
(25(OH)D) and PTH levels were measured at 30- or 36-month OAI visit.
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space narrowing (JSN) score (deﬁned as any increase in JSN score,
including within-grade changes) between the 24- and 48-month OAI
visits, change in medial-to-lateral peri-articular bone mineral density
ratio at the tibial plateau (M:L paBMD ratio), and change in four MRI
trabecular morphometry measures: apparent bone volume fraction
(aBV/TV), apparent trabecular thickness (aTb.Th), number (aTb.N), and
spacing (aTb.Sp) between baseline and follow-up visits. We used
multivariate logistic or linear regression models to analyze the associ-
ations of serum 25(OH)D and PTH levels with OA progression after
adjusting for age, sex, race, study site, body mass index, dietary and
supplemental intake of vitamin D, and season of blood drawn when
they changed the parameter estimates  10%.
Results: The mean levels of serum 25(OH)D and PTH at baseline were
65. 5 nmol/L and 54.5 pg/mL, respectively. Serum 25(OH) D and PTH
levels were negatively correlated (Pearson r ¼ - 0.29, p<0.0001).
Between the baseline and follow-up visits, 14.1% of the study partici-
pants had an increase in JSN score. The M:L paBMD ratio increased by
0.001 (SD¼0.05). Changes in log-transformed aBV/TV, aTb.Th, aTb.N
and aTb.Sp were -0.02, 0.01 mm, -0.03 mm-1, and 0.04 mm respectively
(SD¼0.35, 0.09, 0.29, and 0.35). Participants with low serum vitamin D
levels (<37.5 nmol/L or 15 ng/ml) had more than two-fold elevated risk
of having an increase in JSN score than those with high vitamin D levels
(37.5 nmol/L; OR¼2.3, 95%CI: 1.1-4.5). Serum PTH level was not
associated with increases in JSN score. Neither serum 25(OH)D nor PTH
was associated with changes in M:L paBMD ratio or changes in
trabecular morphometry.
Conclusion: Low serum level of vitamin D is associated with an
increased risk of progression in joint space narrowing in knees with
OA. Changes in peri-articular tibial bone mineral density and trabec-
ular morphometry were small and not related to vitamin D or PTH
levels.Table 1
Baseline demographic, dietary and behavioral factors by serum levels of 25(OH)D (nmol
Total (N¼488)
Age(yr), mean  SD 63.9  9.1
Female, % 47.1
Non-Hispanic white, % 73.8
Body mass index (kg/m2), mean  SD 29.7  4.6
PASE score, mean  SD 168.1  82.2
Alcohol 1drink/day, % 14.2
Smokers, % 54.8
Dietary and supplemental intake of vitamin D
(IU/day)2, median (Q1-Q3)
257.9 (102.7-444.3)
Users of vitamin D supplement, % 65.4
Winter/spring seasons of blood draw, % 49.8
History of knee injury or surgery, % 58.6
1. P values were calculated from ANOVA (age, body mass index, PASE score), Kruskal-Wall
smoking, supplemental vitamin D use, season of blood draw and history of knee injury
2. Values of vitamin D intake were adjusted for total energy intake.
Table 2
Serum levels of 25(OH)D and PTH in association with OA progression in JSN score1, the O
All subjects (N¼418) Subjects with preexi
Not progress / Progress OR (95%CI)1 Not progress / Progr
25 (OH)D (nmol/L)2
 37.5 308 / 51 1.0 190 / 38
< 37.5 44 / 15 2.3 (1.1-4.5) 28 / 15
PTH (pg/mL)2
< 50 180 / 27 1.0 109 / 24
 50 179 / 32 1.1 (0.6-2.0) 109 / 29
1. OA progression in JSN score is deﬁned any increase in JSN score between baseline and
2. Logistic regression model for serum 25(OH)D and joint space narrowing was adjusted
logistic regression model for serum PTH and joint space narrowing was adjusted for
supplemental intake of vitamin D (400 vs. <400 IU/day).34
NIGHT-TIME SPLINTING OF THE DISTAL INTERPHALANGEAL JOINT
REDUCES PAIN AND IMPROVES EXTENSION AT THE JOINT: RESULTS
FROM THE SPLINT-OA STUDY
F.E. Watt y, D. Kennedy z, K. Carlisle z, A. Freidin y, R. Szydlo x, L.
Honeyﬁeld z, K. Satchithananda z, T.L. Vincent y. yKennedy Inst. of
Rheumatology, Univ. of Oxford, Oxford, United Kingdom; zCharing Cross
Hosp., Imperial Coll., London, United Kingdom; xHammersmith Hosp.,
Imperial Coll., London, United Kingdom
Purpose: Distal interphalangeal (DIP) joint osteoarthritis is common
but has few cost-effective, evidence-based interventions. Pain, defor-
mity (radial or ulnar deviation of the joint) and loss of full extension
(extension lag) frequently lead to both functional and cosmetic issues.
Whilst thermoplastic splinting of the ﬁrst carpometacarpal joint is
effective in improving pain, splinting of the interphalangeal joints is not
currently an accepted therapeutic option. We investigated whether
splinting the DIP joint would improve pain, function and deformity.
Methods: A prospective, radiologist-blinded, controlled trial of custom
splinting of the DIP joint was carried out. 26 subjects with symptomatic
hand osteoarthritis gave written, informed consent. All had at least 2
‘affected’ DIP joints (pain2/10 on a numerical rating scale, and at least
7 radial/ulnar deviation +/-extension lag) and were on stable therapies
prior to, and during the study. One intervention joint and one control
joint (which remained un-splinted - there being no satisfactory
placebo) were nominated. Where possible, the contralateral, same digit
DIP joint was the ‘perfect match’ control. A custom ‘gutter’ splint was
worn on consecutive nights (maximum 12 hours/day) for 3 months,
with clinical assessment and measurement of joint deviation (un-
splinted) by digital plain radiograph at baseline and after 3 months.
Statistics: Differences in change in intervention and control joint/L), the Osteoarthritis Initiative, 2007-2009.
25(OH)D  37.5 nmol/L
(N¼415)
25(OH)D <37.5 nmol/L
(N¼73)
P value1
64.3  9.1 61.7  9.0 0.02
47.5 45.2 0.72
78.1 49.3 <0.0001
29.3  4.5 31.9  4.7 <0.0001
167.7  82.0 170.5  83.4 0.78
14.5 12.5 0.65
56.1 47.2 0.16
277.9 (117.3-463.2) 110.1 (57.8-254.4) <0.0001
69.5 41.7 <0.0001
48.0 60.3 0.052
59.8 52.1 0.22
is test (dietary intake of vitamin D) and chi-square test (sex, race/ethnicity, drinking,
or surgery).
steoarthritis Initiative, 2007-2009.
sting OA (N¼271) Subjects without preexisting OA (N¼147)
ess OR (95%CI)1 Not progress / Progress OR (95%CI)1
1.0 118 / 6 1.0
3.2 (1.5-6.8) 23 / 0 –
1.0 71 / 3 1.0
1.1 (0.6-1.2) 70 / 3 0.7 (0.1-4.0)
follow-up visits.
for age (continuous) and supplemental intake of vitamin D (400 vs. <400 IU/day);
age (continuous), BMI (continuous), season (summer/fall vs. winter/spring) and
